



# Evolution in Practice Patterns and Differences Among Experts and Community Healthcare Providers in the Treatment of Patients With Chronic Lymphocytic Leukemia

CLINICAL CARE OPTIONS<sup>®</sup>  
ONCOLOGY

Bing-E Xu, PhD<sup>1</sup>; Kristen M. Rosenthal, PhD<sup>1</sup>; Krista Marcello<sup>1</sup>; Ryan P. Topping, PhD<sup>1</sup>; Farrukh T. Awan, MD, MS<sup>2</sup>; Steven E. Coutre, MD<sup>3</sup>; Nicole Lamanna, MD<sup>4</sup>; Jeff P. Sharman, MD<sup>5</sup>; Timothy A. Quill, PhD<sup>1</sup>; Kevin L. Obholz, PhD<sup>1</sup>; Andrew D. Zelenetz, MD, PhD<sup>6</sup>

1. Clinical Care Options. 2. Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center. 3. Stanford Cancer Center, Stanford University School of Medicine. 4. Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center. 5. Willamette Valley Cancer Institute, US Oncology Research. 6. Memorial Sloan Kettering Cancer Center.

## Background

- Targeted therapies are dramatically changing the treatment landscape for chronic lymphocytic leukemia (CLL)
- Given the rapid pace of new approvals and expanded indications for targeted agents in CLL, healthcare providers (HCPs), particularly those practicing in community settings with limited experience in CLL, can be challenged to make treatment decisions that optimize outcomes for their patients
- To assist HCPs in managing patients with CLL, we have developed and regularly updated an online treatment decision support tool in collaboration with CLL experts
- Here, we report an analysis of data from the 2 most recent CLL tool iterations capturing differences in practice patterns among HCPs compared with CLL experts over time and the impact of case-specific expert recommendations on HCP treatment decisions

## Tool Design and Analysis

- 5 experts provided treatment recommendations for different case scenarios in the newly diagnosed and relapsed/refractory disease settings for each iteration of the tool:
  - Case scenarios based on factors experts considered important for treatment selection, including age, fitness, cytogenetic abnormalities, IGHV mutation status, and previous treatment
  - Expert recommendations compiled in March 2017 (2017 version) and September 2018 (2018 version)
- 2018 expert panel: Farrukh T. Awan, MD, MS; Steven E. Coutre, MD; Nicole Lamanna, MD; Jeff P. Sharman, MD; Andrew D. Zelenetz, MD, PhD
- To use the tool, HCPs enter their patients' information and their intended treatment plan; expert recommendations for their specific patient scenario are then provided
- Current tool available online at [clinicaloptions.com/CLLTool](http://clinicaloptions.com/CLLTool)

## Tool Screenshot Examples

**1. Entry of patient characteristics**

**2. Entry of intended treatment**

**3. Expert recommendations displayed**


Expert	Treatment Regimen	Comments
Expert 1	Venetoclax	
Expert 2	Venetoclax	Would consider alloSCT or CAR T for eligible patients or idelalisib + rituximab.
Expert 3	Venetoclax	
Expert 4	Venetoclax + rituximab	Consider alloSCT if MRD-negative state is not achieved.
Expert 5	Venetoclax + antibody (rituximab or obinutuzumab)	

- This analysis compared the intended treatment of HCPs with expert recommendations for specific cases entered in the tool:
  - 2017 version: March to July 2017
  - 2018 version: October 2018 to July 2019

## Results

### Tool Participant Demographics

- 2017 version: 753 patient cases entered by 406 HCPs
- 2018 version: 656 patient cases entered by 363 HCPs




### Characteristics of Patient Cases Entered by HCPs

Case Characteristics, n (%)	2017 Tool (n = 753)	2018 Tool (n = 656)
<b>Treatment setting</b>		
▪ Newly diagnosed	478 (63)	443 (68)
▪ Relapsed/refractory	275 (37)	213 (32)
<b>Presence of del(17p) or TP53 mutation</b>		
▪ Yes	250 (33)	216 (33)
▪ No	468 (62)	440 (67)
▪ Unknown	35 (5)	0 (0)
<b>Presence of IGHV mutation*</b>	(n = 315)	(n = 310)
▪ Yes	97 (31)	99 (32)
▪ No	114 (36)	117 (38)
▪ Unknown	104 (33)	94 (30)


\*Only asked for newly diagnosed patients without del(17p) and TP53 mutation.

### Impact of Expert Recommendations on Treatment Plan




Tool impact questions were optional and available after users received expert recommendations.


### Patients With del(17p) or TP53 Mutation: First-line Treatment




### Patients Without del(17p) or TP53 Mutation: First-line Treatment in Young and Fit Patients



### Patients With del(17p) or TP53 Mutation: Second-Line Treatment After Ibrutinib



### Patients Without del(17p) or TP53 Mutation: Second-line Treatment After Chemoimmunotherapy



## Conclusions

- Practice patterns for the management of patients with CLL differ considerably between experts and community HCPs
- Expert recommendations were generally consistent in both the 2017 and 2018 tool iterations, and there was consensus for most cases
- There appears to be an increased alignment in treatment choice by HCPs and expert recommendations from 2017 to 2018
- Among HCPs who used this tool, more than one half indicated that the expert recommendations would change their intended treatment plan, suggesting that this online treatment decision support tool can help optimize the care of patients with CLL by aligning community practice with expert recommendations

### Acknowledgments and Disclosures

The CME program that included this tool was supported by unrestricted educational grants from AbbVie, AstraZeneca, Genentech, Janssen, and Pharmacia. Bing-E Xu, PhD; Kristen M. Rosenthal, PhD; Krista Marcello; Ryan P. Topping, PhD; Timothy A. Quill, PhD; and Kevin L. Obholz, PhD, have no relevant financial relationships to disclose. Farrukh T. Awan, MD, MS, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, Genentech, Gilead, Janssen, Pharmacia, and Sunesis and funds for research support from Pharmacia. Steven E. Coutre, MD, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, Astellas, BeiGene, Celgene, Genentech, Janssen, and Pharmacia and funds for research support from AbbVie, Acerta, Celgene, Gilead, and Janssen. Nicole Lamanna, MD, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, BeiGene, Celgene, Genentech, Gilead, Janssen, Juno, and Pharmacia and funds for research support from AbbVie, Acerta, AstraZeneca, BeiGene, Genentech, Gilead, Infinity/Verastem, Juno, Ming, Oncernal, and TG Therapeutics. Jeff P. Sharman, MD, has disclosed that he has received consulting fees and funds for research support from AbbVie, Acerta, AstraZeneca, Celgene, Genentech, Gilead, Janssen, Pharmacia, Seattle Genetics, and TG Therapeutics. Andrew D. Zelenetz, MD, PhD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Bayer, BeiGene, Celgene, DAVA Oncology, Genentech/Roche, Gilead, Janssen, Karyopharm, MEI Pharma, MorphoSys, Novartis, Pfizer, Pharmacia/AbbVie, and Verastem.